NASDAQ:FOLD
Amicus Therapeutics Stock News
$10.61
+0.280 (+2.71%)
At Close: Apr 19, 2024
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
07:00am, Friday, 01'st Sep 2023
PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in
FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss
01:42pm, Wednesday, 09'th Aug 2023
FATE reports a lower-than-expected loss on a decline in operating expenses in the second quarter of 2023.
Amicus (FOLD) Misses on Q2 Earnings, Raises Revenue Guidance
10:42am, Wednesday, 09'th Aug 2023
Amicus (FOLD) incurs wider-than-expected loss in the second quarter. Fabry disease drug Galafold reports encouraging revenues and the company raises its 2023 guidance for the same.
Amicus Therapeutics Inc. (FOLD) Q2 2023 Earnings Call Transcript
03:29pm, Tuesday, 08'th Aug 2023
Amicus Therapeutics Inc. (NASDAQ:FOLD ) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President
Why Earnings Season Could Be Great for Amicus Therapeutics (FOLD)
09:53am, Monday, 07'th Aug 2023
Amicus Therapeutics (FOLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
3 Top Breakout Stocks to Invest in for Excellent Returns
08:14am, Thursday, 03'rd Aug 2023
First Watch Restaurant Group (FWRG), VersaBank (VBNK), and Amicus Therapeutics (FOLD) have been selected as the breakout stocks for today.
Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023
07:00am, Monday, 31'st Jul 2023
PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, August 8, 2023, at 8:
Amicus (FOLD) Gets Approval in Europe for Pompe Disease Drug
12:06pm, Wednesday, 28'th Jun 2023
Amicus (FOLD) receives approval for Opfolda (miglustat) from the European Commission to treat the adult late-onset Pompe disease.
Why Is Amicus Therapeutics (FOLD) Up 8.1% Since Last Earnings Report?
12:42pm, Friday, 09'th Jun 2023
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
Amicus Therapeutics: Finally The FDA Inspection Is Done, Time To Be Positive
04:25pm, Monday, 22'nd May 2023
The FDA inspected the WuXi facility this month, and Amicus Therapeutics, Inc. expects approval in the third quarter. Galafold revenue is growing, although the ANDA challenge needs to be resolved.
Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow
09:10am, Thursday, 11'th May 2023
Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates.
Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates
09:56am, Wednesday, 10'th May 2023
Amicus Therapeutics (FOLD) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.30 per share a year ago.
Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023
07:00am, Monday, 01'st May 2023
PHILADELPHIA, May 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2023, at 8:3
These Are the Top 10 Holdings of Avoro Capital Advisors
10:54pm, Monday, 17'th Apr 2023
Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.
The FDA Is Resuming Drug Lab Inspections in China. These Biotechs Could Benefit.
02:45pm, Friday, 14'th Apr 2023
China's pandemic-era travel restrictions paused approvals on some new drugs. The end of Zero Covid means the pipeline will reopen.
